Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 This research ... PBS, Starch Based Plastics, Regenerated Cellulose, PCL), by ... Trends and Forecasts to 2019”, defines and segments ... and forecast of its global volume and value. ... Figures spread through 178 Slides and in-depth TOC ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 A new ... overcome several pitfalls of current skin grafting technologies, it ... produces hair. The method, outlined in the October issue ... for treating deep skin injuries that result from severe ... completely destroys the skin’s regenerative elements. These wounds heal ...
(Date:10/25/2014)... NEW YORK , Oct. 24, ... formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company ... has implemented a 1-for-50 reverse split of its ... on Friday, October 24, 2014. PlasmaTech,s common stock ... CUSIP number 72754H109 and temporary ticker symbol "ACCPD". ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3
... in a hexagonal, chicken wire structure holds great ... conductive, graphene may one day replace conventional silicon microchips, ... In addition to potential applications in integrated circuits, solar ... material has attracted the attention of physicists for its ...
... Inc. (NYSE Amex: NBS ), an international biopharmaceutical company ... will present on a panel at the 31st Annual Cowen Group ... March 7, 2011 at 1 PM and Dr. Robin Smith, the ... at 10:15 AM. The Conference will be held at the Boston ...
... Corporation (Nasdaq: VOLC ), a leading developer ... enhance the diagnosis and treatment of coronary and peripheral ... market the Eagle Eye® Platinum digital IVUS catheter in ... PCI Live Demonstration Course in Kurashiki, which starts on ...
Cached Biology Technology:Probing atomic chicken wire 2Probing atomic chicken wire 3Probing atomic chicken wire 4NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8 2NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8 3Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 2Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 3
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... Mary,s Virginia Institute of Marine Science have received ... Agency to identify the streams and wetlands most ... to help local governments and citizens conserve these ... a dataset of tidal-marsh observations first gathered by ... historical baseline can today,s researchers accurately map the ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... experiences trauma or disease, such as muscular dystrophy, ... cells" respond to repair and regenerate the muscle. ... such as muscular dystrophy, which affect muscle stability ... used time-lapse photography to document satellite cell movements ...
... PHILADELPHIA Although acute myeloid leukemia (AML) is relatively ... the risk, according to a recent paper published in ... of the American Association for Cancer Research. Julie ... and clinical research at the University of Minnesota, said ...
... to the poles, and you,ll notice that the ... equator. Move from lowland to mountains, and you,ll ... varied. Ecologists have proposed various explanations for these ... processes. New findings by University of ...
Cached Biology News:Caught on tape: Muscle stem cells captured on video by MU researcher 2Climate change and mountain building led to mammal diversity patterns 2
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... General description: Workstation for PCR set-up ... 96 MicroWell format to hold 0.2 ml PCR tubes, ... compatible with automated handling systems Removable tray ... Compatible with V-bottom 0.2 ml tube block thermal ...
Biology Products: